The company has been actively expanding its product pipeline, with over 70 commercialized products and a healthy pipeline of 100+ approved products.

The stock gave multibagger returns of over 200 per cent in just 1 year and a whopping 400 per cent in 2 years.

Of significant note is the remarkable reduction in the company's debt-to-EBITDA ratio, which has undergone a substantial decline from 5.7x in FY'22 to 2.8x on an annualized quarterly basis, signaling a notable financial transformation. Despite surpassing guidance in debt reduction, the company continues to generate free cash flow

The stock has surged nearly 107 per cent in the last year, transforming into a multibagger stock for investors.